Strata Critical Medical (SRTA) Liabilities and Shareholders Equity (2019 - 2026)

Strata Critical Medical has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $327.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 30.76% year-over-year to $327.6 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 16.4% YoY), while the FY2025 annual figure was $325.5 million, up 26.8% from the prior year.
• Liabilities and Shareholders Equity rose to $327.6 million in Q1 2026, from $325.5 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for SRTA reached as high as $335.1 million in Q3 2025 and fell as low as $250.6 million in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $320.2 million (2023), against an average of $303.3 million.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity decreased 12.97% — and 2026, when it jumped 30.76%.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $325.0 million in 2022, then dropped by 9.26% to $294.9 million in 2023, then declined by 12.97% to $256.7 million in 2024, then rose by 26.8% to $325.5 million in 2025, then rose by 0.66% to $327.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $327.6 million, $325.5 million, and $335.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.